Information Provided By: 
Fly News Breaks for March 9, 2016
TEVA
Mar 9, 2016 | 06:43 EDT
Citi analyst Liav Abraham lowered his price target for Teva to $75 from $86 but says the company remains a preferred name. The company is well positioned within a sector where the focus has shifted to fundamentals versus takeovers, Abraham tells investors in a research note. He estimates Teva's pipeline is worth $21 per share that is not reflected in the valuation. The analyst keeps a Buy rating on the name.
News For TEVA From the Last 2 Days
